Genmab A/S (GNMSF)
OTCMKTS · Delayed Price · Currency is USD
330.63
0.00 (0.00%)
At close: Feb 3, 2026
Genmab Market Cap
Genmab has a market cap or net worth of $19.08 billion as of February 6, 2026. Its market cap has increased by 42.67% in one year.
Market Cap
19.08B
Enterprise Value
15.79B
Revenue
3.85B
Ranking
n/a
PE Ratio
12.05
Stock Price
$330.63
Market Cap Chart
Since October 18, 2000, Genmab's market cap has increased from 415.12M to 19.08B, an increase of 4,496.22%. That is a compound annual growth rate of 16.32%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 5, 2026 | 19.33B | -1.71% |
| Dec 30, 2025 | 19.67B | 49.05% |
| Dec 30, 2024 | 13.19B | -36.79% |
| Dec 29, 2023 | 20.88B | -24.42% |
| Dec 30, 2022 | 27.62B | 5.40% |
| Dec 30, 2021 | 26.20B | -1.50% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Northwest Biotherapeutics | 421.57M |
| CytoDyn | 311.73M |
| Silence Therapeutics | 203.11M |
| Vaxart | 150.68M |
| HST Global | 139.70M |
| BioStem Technologies | 100.03M |
| Nuo Therapeutics | 78.70M |
| VitaSpring Biomedical | 51.78M |